Monitoring Migraine Biologics: Safety Insights Revealed

Research Summary

The paper "Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics," published in Frontiers in Pharmacology, highlights the importance of vigilant pharmacovigilance in the use of biologic drugs, especially monoclonal antibodies targeting Calcitonin Gene-Related Peptide (CGRP) for migraine treatment. The authors emphasize that while the FDA has approved numerous biologics, there remains a scarcity of data regarding their long-term safety and efficacy. This review compiles existing data from both pre-marketing trials and real-world post-marketing studies, underscoring the necessity for ongoing monitoring to address the risks associated with these chronic-use medications.

Study Details

📄 Title: Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics.

👥 Research Team: Guarnieri L et al.

📚 Published In: Front Pharmacol

📅 Publication Date: 2026

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.